

**Statement showing the Firm wise Provisional Technical Evaluation Report for
Tender Notice No :42(19-20)/APMSIDC/Medicine Wing/2019-21, Dt: 31.08.2019.**

<i>Sl.No</i>	<i>Firm Name</i>	<i>Item Code</i>	<i>Item Name</i>	<i>Specification</i>	<i>Description</i>	<i>Provisional Item Remarks</i>	<i>Provisional Status</i>
1	Cadila Pharmaceuticals Limited	<i>Provisional Firm Remarks :</i>					
		1631	Human Premixed Insulin Injection IP 30/70 in 10 ml vial	10 ml vial	5 X 5 ,Type-1 Glass		May Be Considered
2	Cipla Ltd	<i>Provisional Firm Remarks :</i>					
		2201	Abacavir 600mg + Lamivudine 300 mg Tab I.P	Abacavir 600mg + Lamivudine 300 mg	10 X 1 0 (Or) 50 X 10 White Opaque Blister With Aluminum Foil Pack		May Be Considered
		1745	Budesonide Nebulising solution 0.5mg	0.5mg	2ml X 5X5 and 2ml X 5X4X60	Not enclosed product license copy.	May Not Be Considered
		2220	Budesonide Respules Solution 0.5 mg/2 ml	0.5 mg/2 ml	1 X 25		May Be Considered
		1792	Efavirenz Capsules IP 200mg	200mg	10 X 10 Or 50X10 Blister With Aluminum Foil Pack		May Be Considered
		2087	Entacavir Tab 0.5mg	Each Film Coated Tablet Contains: Entecavir 0.5 Mg Colour: Titanium Dioxide Ip	10 X 10 Or 50 X 10 Blister With Aluminum Foil Pack		May Be Considered
		1805	Finasteride Tablets IP 5mg	5mg	10 X 10 Or 50 X 10 Blister With Aluminum Foil Pack		May Be Considered
		1812	Flutamide Tablets USP 250 mg	250 mg	10 X 10 Or 50 X 10 Blister With Aluminum Foil Pack		May Be Considered
		1894	Nevirapine Tablets IP 200mg	200mg	10 X 10 Or 50X10 Blister With Aluminum Foil Pack		May Be Considered
		2417	Salbutamol MDI	100 mcg per dose 200 metered doses	1 X 10 Inhalers		May Be Considered
		1656	Salbutamol Nebulising solution IP 10ml	10ml	5 X 5		May Be Considered
		2422	Sildenafil Citrate 20mg Tablet	20mg	10 X 10 or 5x10x10 Blister with Aluminum Foil Pack		May Be Considered
		2160	Tenofovir Tab 300mg	300mg	10X10 Or 50X10 Blister With Aluminum Foil Pack		May Be Considered
		1968	Tolterodine Tartrate Capsules 2mg	Each capsule contains: Tolterodine Tartrate-2mg (as extended release pellets)	10 X 10 Or 50X10 Blister With Aluminum Foil Pack		May Be Considered

<i>Sl.No</i>	<i>Firm Name</i>	<i>Item Code</i>	<i>Item Name</i>	<i>Specification</i>	<i>Description</i>	<i>Provisional Item Remarks</i>	<i>Provisional Status</i>
3	<i>Eisai Pharmaceuticals India Private Limited</i>					<i>Provisional Firm Remarks :</i>	
		1	2377	Pegylated Interferon Beta Injection 1 a 125 mcg/ 0.5ml	1 a 125 mcg/ 0.5ml	1 X 10 Amps	May Be Considered
4	<i>Ferring Pharmaceuticals Private Limited</i>					<i>Provisional Firm Remarks :</i>	
		1	1781	Desmopressin Nasal Spray 1mcg /5ml	1mcg /5ml	1 X 50 (or) 1 X 25	Strength variation. May Not Be Considered
5	<i>M.J.Biopharm Pvt. Ltd.,</i>					<i>Provisional Firm Remarks :</i>	
		1	1631	Human Premixed Insulin Injection IP 30/70 in 10 ml vial	10 ml vial	5 X 5 ,Type-1 Glass	May Be Considered
6	<i>Merck Specialities Pvt Ltd</i>					<i>Provisional Firm Remarks :</i>	
		1	2237	Cetuximab Injection 100mg/20ml	100mg/20ml	1 X10 Vials Type 1 Glass	May Be Considered
7	<i>Mylan Laboratories Limited</i>					<i>Provisional Firm Remarks :</i>	
		1	2427	Sofosbuvir 400mg +Valpatasvir 100mg tablets	400mg +100mg	10 X 10 Aluminium Blister Packs	May Be Considered
		2	2160	Tenofovir Tab 300mg	300mg	10X10 Or 50X10 Blister With Aluminum Foil Pack	May Be Considered
		3	1852	Zidovudine + Lamivudine Tab IP	Zidovudine 300 mg Lamivudine +150 mg	30 Capsules In A HDPE White Colour Bottle	May Be Considered
8	<i>Pharma Impex Laboratories Private Limited</i>					<i>Provisional Firm Remarks : May be considered after submission of WHO-GMP Certificate.</i>	
		1	1437	Isolyte-M Injection	Each 100ml Contains Dextrose (As Anhydrous) IP5.0G, Sodium Chloride Ip0.1G, Sodium Acetate IP 0.28G, Potassium Chloride 0.15G, Disabsic Pottasium Phospate USP 0.13G, Water For Injection Ipqs, Stabiliser Sodium Metabisulphit, Ipqs Ph-Adjusted With HCL1,00	500ml Plastic Bottle 4X6 (Separation Between Bottles is Must).	May Be Considered

<i>Sl.No</i>	<i>Firm Name</i>	<i>Item Code</i>	<i>Item Name</i>	<i>Specification</i>	<i>Description</i>	<i>Provisional Item Remarks</i>	<i>Provisional Status</i>
2		391	Isolyte-P Injection	Each 100ml contains Dextrose (as anhydrous) IP5.0G, Potassium Chloride IP0.13G, Sodium Acetate IP0.32G, Dibasic Potassium Phosphate USP0.0269, Magnesium Chloride IP0.031G, water for injection IPQS, Stabiliser sodium Metabisulphite IPQS, Ph adus with HCL	500ml Plastic Bottle 1 X 4 X 6 Equal to 24 Bottles		May Be Considered
9	Serum Institute Of India Ltd.,			<i>Provisional Firm Remarks : May be considered after submission of document proof for Authorised signatory.</i>			
1		1511	Rabies Vaccine Human use (Cell Culture) IP ID ROUTE	1ml with 5 ID Syringes	1ml with 5 ID Syringes		May Be Considered

Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their objections and supporting documents on or before 5 p.m on 06.11.2019 to the email: tenders.apmsidc@gmail.com and apmsidc.gm@gmail.com